These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 10856587

  • 1. Daclizumab in live donor renal transplantation.
    Iverson AJ, Vick SC, Sarnacki CT, Wright FH.
    Transplant Proc; 2000 Jun; 32(4):790-2. PubMed ID: 10856587
    [No Abstract] [Full Text] [Related]

  • 2. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
    Ivanovski N, Popov Z, Kolevski P, Cakalaroski K, Spasovski G, Sikole A, Paneva-Masin J.
    Transplant Proc; 2001 Jun; 33(7-8):3203-4. PubMed ID: 11750374
    [No Abstract] [Full Text] [Related]

  • 3. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation.
    Vincenti F.
    Transplant Proc; 1999 Sep; 31(6):2206-7. PubMed ID: 10500546
    [No Abstract] [Full Text] [Related]

  • 4. Effect of daclizumab (zenapax) on prevention of acute rejection of renal transplantation.
    Poorrezagholi F, Einollahi B, Firoozan A, Nafar M, Yadegari H, Moghaddam SM, Simforoosh N, Basiri A, Farhangi S.
    Transplant Proc; 2003 Nov; 35(7):2735-6. PubMed ID: 14612098
    [No Abstract] [Full Text] [Related]

  • 5. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW, Ciancio C, Blomberg BB, Rosen A, Suzart K, Roth D, Kupin W, Esquenazi V, Miller J.
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract] [Full Text] [Related]

  • 6. Cyclosporine microemulsion (Neoral) versus tacrolimus (FK506) as maintenance therapy in kidney transplant patients.
    Abou-Jaoude MM, Irani-Hakime N, Ghantous I, Najm R, Afif C, Almawi WY.
    Transplant Proc; 2003 Nov; 35(7):2748-9. PubMed ID: 14612103
    [No Abstract] [Full Text] [Related]

  • 7. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.
    Vincenti F, Nashan B, Light S.
    Transplant Proc; 1998 Aug; 30(5):2155-8. PubMed ID: 9723424
    [No Abstract] [Full Text] [Related]

  • 8. Daclizumab to prevent acute rejection in renal transplantation.
    Abramowicz D.
    N Engl J Med; 1998 Jun 04; 338(23):1700-1. PubMed ID: 9616069
    [No Abstract] [Full Text] [Related]

  • 9. The role of newer monoclonal antibodies in renal transplantation.
    Vincenti F.
    Transplant Proc; 2001 Jun 04; 33(1-2):1000-1. PubMed ID: 11267163
    [No Abstract] [Full Text] [Related]

  • 10. Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation.
    Charpentier B, Thervet E.
    Transplant Proc; 1998 Jun 04; 30(4):1331-2. PubMed ID: 9636541
    [No Abstract] [Full Text] [Related]

  • 11. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results.
    Martins L, Henriques AC, Dias L, Sarmento AM, Pereira MC, Guimarães S.
    Transplant Proc; 2000 Dec 04; 32(8):2623-5. PubMed ID: 11134730
    [No Abstract] [Full Text] [Related]

  • 12. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 13. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
    Innocenti F, Humeres R, Zamboni M, Sanhueza E, Zapata R, Hepp J, Rius M.
    Transplant Proc; 2003 Nov 27; 35(7):2520-1. PubMed ID: 14612001
    [Abstract] [Full Text] [Related]

  • 14. Use of daclizumab in the immunosuppression of high-risk kidney and kidney/pancreas recipients: Warsaw Transplantation Center experience.
    Baczkowska T, Kukula K, Nowacka-Cieciura E, Cieciura T, Lewandowska D, Ciecierski R, Grochowiecki T, Rowinski W, Szmidt J, Durlik M, Lao M.
    Transplant Proc; 2002 Mar 27; 34(2):551-2. PubMed ID: 12009620
    [No Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group.
    Hengster P, Pescovitz MD, Hyatt D, Margreiter R.
    Transplantation; 1999 Jul 27; 68(2):310-3. PubMed ID: 10440409
    [Abstract] [Full Text] [Related]

  • 16. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B, Light S, Hardie IR, Lin A, Johnson JR.
    Transplantation; 1999 Jan 15; 67(1):110-5. PubMed ID: 9921806
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G, Burke GW, Suzart K, Vaidya A, Roth D, Kupin W, Mattiazzi A, Rosen A, Esquenazi V, Miller J.
    Transplant Proc; 2003 Mar 15; 35(2):873-4. PubMed ID: 12644172
    [No Abstract] [Full Text] [Related]

  • 18. Could prophylactic monoclonal antibody improve kidney graft survival?
    Pourmand G, Saraji A, Salem S, Mehrsai A, Nikoobakht MR, Taherimahmoudi M, Rezaeidanesh M, Asadpour A.
    Transplant Proc; 2009 Sep 15; 41(7):2794-6. PubMed ID: 19765437
    [Abstract] [Full Text] [Related]

  • 19. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups.
    Ekberg H, Bäckman L, Tufveson G, Tydén G.
    Transplant Proc; 1999 Sep 15; 31(1-2):267-8. PubMed ID: 10083102
    [No Abstract] [Full Text] [Related]

  • 20. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
    Sánchez-Fructuoso AI, Prats D, Marques M, Ridao N, Conesa J, García Mena M, Torrente J, Barrientos A.
    Transplant Proc; 2003 Aug 15; 35(5):1689-90. PubMed ID: 12962759
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.